Latest Regulatory News

Equus Energy has launched on the ASX with full ownership of the Equus Gas Project, backed by a $46 million conditional funding and gas sales agreement with Alcoa. The project aims to supply a significant new gas source for Western Australia’s LNG and domestic markets.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

American Tungsten & Antimony Ltd has acquired the Dutch Mountain Tungsten Project and its fully permitted processing facility in Utah, positioning itself to accelerate tungsten production in the US by bypassing lengthy federal permitting.

Stockland announces a 9-cent unfranked dividend for the half-year ending December 2025, alongside a Dividend Reinvestment Plan priced at $5.47 per security. The DRP offers investors a 1% discount and new securities issued will rank equally from the issue date.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

Rapid Critical Metals has launched a comprehensive scoping study for its NSW silver projects, backed by promising drilling results and advanced ore-sorting technology.

29Metals Limited has initiated a fully underwritten $150 million entitlement offer at $0.40 per share, aiming to bolster its growth projects and operational recovery following seismic disruptions. The retail offer opens on 28 January and closes on 11 February 2026.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

Clever Culture Systems has expanded its APAS Independence installed base to 27 instruments globally and surpassed $1 million in annual recurring revenue, underpinned by strong sales momentum and customer validation.